Goldman Sachs
ARCT icon

Goldman Sachs’s Arcturus Therapeutics ARCT Stock Holding History

Goldman Sachs’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,300
Closed -$241K – 6243
2022
Q2 		$241K Buy
+15,300
New +$300K ﹤0.01% 5550
2014
Q4 		– Sell
-24,929
Closed -$2.69M – 7101
2014
Q3 		$2.69M Buy
24,929
+24,843
+28,887% +$3.24M ﹤0.01% 3644
2014
Q2 		$10K Buy
+86
New +$10.4K ﹤0.01% 6923

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs's ARCT Position: Q2 2026 in Review

Goldman Sachs increased its Arcturus Therapeutics (ARCT) stake by 56% in Q2 2026, buying an estimated $876K and bringing the position to 309,863 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #4656.

Goldman Sachs first reported a position in ARCT in Q2 2014 and has held it in 39 quarters since. The position peaked at $19.4M in Q4 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Goldman Sachs held 309,863 shares of Arcturus Therapeutics worth $2.08M as of Q2 2026.
  • Goldman Sachs bought 111,182 Arcturus Therapeutics shares in Q2 2026, an estimated $876K.
  • Arcturus Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4656 holding.
  • Goldman Sachs first reported a position in Arcturus Therapeutics in Q2 2014 and has held it in 39 quarters since.
  • Goldman Sachs's Arcturus Therapeutics position peaked at $19.4M in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.